Author Correction: Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis

By afschroeder • February 6, 2026

Li S, Noor ZS, Zeng W, Stackpole ML, Ni X, Zhou Y, Yuan Z, Wong WH, Agopian VG, Dubinett SM, Alber F, Li W, Garon EB, Zhou XJ. Author Correction: Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis. Nat Commun. 2026 Feb 5;17(1):1388. doi: 10.1038/s41467-026-69268-5. Erratum for: Nat Commun. 2021 Jul 7;12(1):4172. doi: 10.1038/s41467-021-24457-2. PMID: 41644545.

Tags: Hematology/Oncology, Publications, Pulmonary, Critical Care & Sleep Medicine

Related Posts

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial

Girard N, Goldman J, Lu S, Bar J, Horinouchi H, Daaboul N, Liu C, Çiçin I, Katgi N, Zer A, Ciuleanu T, Reinmuth N, Planchard[...]

Local partisan context and mental health

Baxter-King R, Brown JR, Enos RD, Naeim A, Vavreck L. Local partisan context and mental health. Proc Natl Acad Sci U S A. 2026 Jul[...]

Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD

Okamoto I, Cho BC, Goldberg SB, Goldman JW, de Langen AJ, Piotrowska Z, Riess JW, Yu HA, Garcia Campelo MR, Cetnar J, Kim YJ, Novello[...]